CPRX
Income statement / Annual
Last year (2023), Catalyst Pharmaceuticals, Inc.'s total revenue was $398.20 M,
an increase of 85.90% from the previous year.
In 2023, Catalyst Pharmaceuticals, Inc.'s net income was $71.41 M.
See Catalyst Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$398.20 M
|
$214.20 M
|
$140.83 M
|
$119.07 M
|
$102.31 M
|
$500,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Cost of Revenue |
$84.53 M |
$34.39 M |
$21.88 M |
$17.04 M |
$14.76 M |
$19.92 M |
$45,689.00 |
$43,406.00 |
$34,468.00 |
$0.00 |
Gross Profit |
$313.67 M |
$179.81 M |
$118.95 M |
$102.03 M |
$87.55 M |
-$19.42 M |
-$45,689.00 |
-$43,406.00 |
-$34,468.00 |
$0.00 |
Gross Profit Ratio |
0.79 |
0.84 |
0.84 |
0.86 |
0.86 |
-38.84 |
0 |
0 |
0 |
0 |
Research and Development
Expenses |
$93.15 M
|
$19.79 M
|
$16.94 M
|
$16.50 M
|
$18.84 M
|
$19.92 M
|
$11.38 M
|
$11.37 M
|
$11.80 M
|
$10.12 M
|
General & Administrative
Expenses |
$47.02 M
|
$28.71 M
|
$23.48 M
|
$20.67 M
|
$33.58 M
|
$15.88 M
|
$7.30 M
|
$7.91 M
|
$8.60 M
|
$4.47 M
|
Selling & Marketing
Expenses |
$86.69 M
|
$29.47 M
|
$26.15 M
|
$23.57 M
|
$3.30 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$133.71 M
|
$58.18 M
|
$49.63 M
|
$44.23 M
|
$36.88 M
|
$15.88 M
|
$7.30 M
|
$7.91 M
|
$8.60 M
|
$4.47 M
|
Other Expenses |
$7.70 M |
$2.88 M |
$282,000.00 |
$586,897.00 |
$1.59 M |
$1.29 M |
$454,163.00 |
$321,612.00 |
$100,389.00 |
$76,233.00 |
Operating Expenses |
$226.86 M |
$77.97 M |
$66.56 M |
$60.73 M |
$55.72 M |
$35.80 M |
$18.68 M |
$19.28 M |
$20.40 M |
$14.59 M |
Cost And Expenses |
$311.39 M |
$112.37 M |
$88.45 M |
$77.77 M |
$70.48 M |
$35.80 M |
$18.68 M |
$19.28 M |
$20.40 M |
$14.59 M |
Interest Income |
$0.00 |
$3.64 M |
$282,000.00 |
$587,000.00 |
$1.59 M |
$1.29 M |
$454,163.00 |
$321,612.00 |
$100,389.00 |
$76,233.00 |
Interest Expense |
$0.00 |
-$4.12 M |
$0.00 |
$0.00 |
$0.00 |
$1.29 M |
$454,163.00 |
$321,612.00 |
$100,389.00 |
$76,233.00 |
Depreciation &
Amortization |
$33.14 M
|
$1.49 M
|
$484,000.00
|
$885,317.00
|
$297,726.00
|
$37,978.00
|
$45,689.00
|
$43,406.00
|
$34,468.00
|
$26,574.00
|
EBITDA |
$119.96 M
|
$101.84 M
|
$52.39 M
|
$41.30 M
|
$31.82 M
|
-$35.30 M
|
-$18.49 M
|
-$20.17 M
|
-$20.46 M
|
-$13.57 M
|
EBITDA Ratio |
0.3 |
0.48 |
0.37 |
0.35 |
0.31 |
-70.59 |
0 |
0 |
0 |
0 |
Operating Income Ratio
|
0.22
|
0.48
|
0.37
|
0.35
|
0.31
|
-70.59
|
0
|
0
|
0
|
0
|
Total Other
Income/Expenses Net |
$7.70 M
|
$2.88 M
|
$282,000.00
|
$586,897.00
|
$1.59 M
|
$1.29 M
|
$267,259.00
|
$1.21 M
|
$165,394.00
|
-$917,633.00
|
Income Before Tax |
$94.51 M |
$104.72 M |
$52.67 M |
$41.89 M |
$33.41 M |
-$34.00 M |
-$18.41 M |
-$18.07 M |
-$20.23 M |
-$15.51 M |
Income Before Tax Ratio
|
0.24
|
0.49
|
0.37
|
0.35
|
0.33
|
-68.01
|
0
|
0
|
0
|
0
|
Income Tax Expense |
$23.10 M |
$21.64 M |
$13.19 M |
-$33.09 M |
$1.53 M |
$2.58 M |
$141,215.00 |
-$929,543.00 |
-$99,473.00 |
$993,866.00 |
Net Income |
$71.41 M |
$83.08 M |
$39.48 M |
$74.98 M |
$31.88 M |
-$34.00 M |
-$18.41 M |
-$18.07 M |
-$20.23 M |
-$15.51 M |
Net Income Ratio |
0.18 |
0.39 |
0.28 |
0.63 |
0.31 |
-68.01 |
0 |
0 |
0 |
0 |
EPS |
0.67 |
0.8 |
0.38 |
0.72 |
0.31 |
-0.33 |
-0.21 |
-0.22 |
-0.25 |
-0.24 |
EPS Diluted |
0.63 |
0.75 |
0.37 |
0.71 |
0.3 |
-0.33 |
-0.21 |
-0.22 |
-0.25 |
-0.24 |
Weighted Average Shares
Out |
$106.28 M
|
$103.37 M
|
$103.38 M
|
$103.51 M
|
$102.94 M
|
$102.63 M
|
$85.80 M
|
$82.88 M
|
$80.86 M
|
$64.14 M
|
Weighted Average Shares
Out Diluted |
$113.75 M
|
$111.38 M
|
$107.80 M
|
$106.24 M
|
$106.02 M
|
$102.63 M
|
$85.80 M
|
$82.88 M
|
$80.86 M
|
$64.14 M
|
Link |
|
|
|
|
|
|
|
|
|
|